Log In
BCIQ
Print this Print this
 

lomibuvir (VX-222) (formerly VCH-222)

  Manage Alerts
Collapse Summary General Information
Company Vertex Pharmaceuticals Inc.
DescriptionNon-nucleoside HCV NS5B polymerase inhibitor
Molecular Target HCV NS5B polymerase
Mechanism of ActionHCV non-structural protein 5B inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection; Treat HCV genotype 1 infection in treatment-naïve patients; Treat HCV infection
Regulatory Designation
PartnerTrek Therapeutics PBC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$413.1M

$100.0M

0


 Deals Details
Get a free BioCentury trial today